New newsletter about BioQuest:
"The Heart of the Matter
- OMF has now received approval from the NIH to access plasma samples collected via the Chronic Fatigue Initiative, bringing the total number of samples for our large-scale ME/CFS biomarker project (BioQuest) to 1,000.
- BioQuest is the largest biomarker study of its kind for ME/CFS, with a geographically diverse cohort, disease controls, and well-characterized patients with doctor-confirmed diagnoses.
- This project builds on a collection of studies that highlight the potential of molecular signals in the plasma to serve as biomarker signatures for ME/CFS. BioQuest will look at metabolomics, proteomics, and cytokines with in-depth analysis, including subgrouping."
"By combining these with samples from our Collaborative Center at Uppsala, we now have samples from 400 people with ME/CFS, 400 healthy controls, and 50 each of disease controls, including multiple sclerosis, exertional malaise (burn out syndrome), clinical depression, and Long COVID. We expect to be able to start testing these samples by the end of 2025."
"The proteomics, metabolomics, and cytokine testing on these 1000 samples is the first phase of our overall biomarker project. The ultimate goal of BioQuest is to identify a biochemical signature for ME/CFS that can be conveniently evaluated through a blood test and will differentiate ME/CFS from other illnesses with similar clinical presentations."
Follow link for full update: https://www.omf.ngo/bioquest-update/